Positive earnings growth hasn't been enough to get BioNTech (NASDAQ:BNTX) shareholders a favorable return over the last year

By
Simply Wall St
Published
May 16, 2022
NasdaqGS:BNTX
Source: Shutterstock

This week we saw the BioNTech SE (NASDAQ:BNTX) share price climb by 17%. But that doesn't change the fact that the returns over the last year have been less than pleasing. The cold reality is that the stock has dropped 18% in one year, under-performing the market.

The recent uptick of 17% could be a positive sign of things to come, so let's take a lot at historical fundamentals.

View our latest analysis for BioNTech

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

BioNTech stole the show with its EPS rocketing, in the last year. We don't think the growth guide to the sustainable growth rate in this case, but we do think this sort of increase is impressive. As you can imagine, the share price action therefore perturbs us. Some different data might shed some more light on the situation.

BioNTech's revenue is actually up 831% over the last year. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
NasdaqGS:BNTX Earnings and Revenue Growth May 16th 2022

BioNTech is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

We doubt BioNTech shareholders are happy with the loss of 18% over twelve months. That falls short of the market, which lost 9.0%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. It's great to see a nice little 2.8% rebound in the last three months. Let's just hope this isn't the widely-feared 'dead cat bounce' (which would indicate further declines to come). I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 2 warning signs for BioNTech that you should be aware of before investing here.

We will like BioNTech better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.